Why Zimbabwe's 2018 Cannabis Export Licences Shut Out Small Growers
Photo via Unsplash.
In April 2018, Zimbabwe's then-Health Minister David Parirenyatwa put his signature on a document that made international headlines for a few days and then quietly reshaped a rural economy that had operated in the shadows for generations. Statutory Instrument 62 of 2018 made Zimbabwe the second country on the African continent, after Lesotho the year before, to legalize cannabis cultivation. The framing at the time was optimistic: a regulated industry, export revenue, a path for growers who'd been working outside the law to come inside it.
The regulations themselves weren't nothing. Licence holders could possess, transport and sell both fresh and dried cannabis along with cannabis oil, under permits that ran five years and could be renewed. But the entry price was $50,000 -- a figure that bore no relationship to what a subsistence farmer in Binga District, where marijuana cultivation had quietly sustained households for decades, could ever hope to raise. MPs said as much on the floor of parliament almost immediately. What followed was eight years of a licensing scheme that, by most honest accounts, did the opposite of what it was sold to do: it built a legal cannabis export industry dominated by foreign joint-venture capital, while the small growers the law was supposedly designed to bring in from the cold stayed exactly where they'd always been.
The Statutory Instrument That Started It All
The regulation's full name is a mouthful -- the Dangerous Drugs (Production of Cannabis for Medicinal and Scientific Use) Regulations -- and it was gazetted on 27 and 28 April 2018 under Parirenyatwa's signature as Statutory Instrument 62. At the time it was treated as a genuine milestone: Zimbabwe became only the second African nation, after Lesotho's 2017 licensing framework, to put cannabis cultivation on a legal footing. That put the country ahead of far wealthier nations on the continent, and ahead of most of the world outside a handful of early-adopting states.
The mechanics were straightforward enough on paper. A licence runs for five years and is renewable, and it covers possession, transport and sale of both fresh and dried cannabis plant material as well as cannabis oil. But the regulation also built in a vetting clause that mattered more in practice than it looked on paper: an application could be refused if there was any indication the applicant had previously diverted a controlled substance into illicit markets. That's a reasonable-sounding safeguard against bad actors, but it quietly favored applicants who could produce clean corporate paperwork, audited financial histories and legal counsel -- registered companies and joint ventures, not farmers who'd been growing mbanje in the hills around Binga without permits because no legal channel had ever existed for them.
There's one more structural detail that shaped everything that followed: cannabis grown under an SI 62 licence is for export only. Domestic consumption isn't part of the model at all, except for strictly defined research and development purposes. Zimbabwe wasn't building a local medical cannabis market for its own patients -- it was building an export crop, licensed and regulated the way tobacco or horticultural exports are, aimed at overseas pharmaceutical buyers. That export orientation explains a lot about who the regulation was actually designed to attract.
A $50,000 Price Tag Nobody in Binga Could Pay
Photo via Pexels.
The $50,000 licence fee became the headline complaint almost as soon as the regulations were published, and it wasn't abstract griping -- members of parliament raised it explicitly on behalf of constituents in districts like Binga, where cannabis had been grown illegally for generations as a cash crop in a region with few other reliable income sources. MPs lobbied publicly for the fee to be reduced, arguing that a scheme marketed as bringing informal growers into the legal fold would do nothing of the sort if the entry fee cost more than most Binga households would see in several years.
But the fee was only part of the problem, and arguably not even the biggest part. The regulations also required licensed growing sites to install air filtration systems specifically to prevent cannabis odour and pollen from escaping the property -- a requirement that makes sense for a tightly controlled pharmaceutical-grade operation but assumes access to industrial ventilation engineering that a smallholder plot in rural Binga simply doesn't have. Add to that mandated security fencing and surveillance equipment, and the compliance bill climbed well past the licence fee itself. Several analysts and critics at the time argued that this physical infrastructure burden -- not the headline $50,000 -- was the real wall keeping small growers out, since even a wealthy local farmer willing to somehow scrape together the application fee still faced a secondary capital outlay for fencing, cameras and ventilation that could rival or exceed it.
And the scheme offered no economies of scale. Each licence was tied to one specific cultivation site. A grower who wanted to farm two or three plots -- which is exactly how smallholder agriculture tends to work in Zimbabwe, with scattered family land rather than a single consolidated farm -- had to pay the fee and meet the infrastructure requirements separately for each one. For a Binga farmer already growing on modest, dispersed plots, that single-site rule didn't just raise the price of entry; it multiplied it by however many fields a family actually worked.
57 Licences, 15 Active: Where the Permits Actually Went
Between 2018 and 2022, Zimbabwe issued 57 cannabis licences but only 15 were actually activated, highlighting a significant gap between licensing approvals and operational farms.
By 2022, Zimbabwe had issued 57 cannabis cultivation licences since the scheme's 2018 launch -- a number that, on its own, supported the country's claim to be among the earliest movers on medicinal cannabis legalization in Africa. Dig one level deeper, though, and the picture gets less flattering. Only 15 of those 57 permits had actually been activated with real cultivation underway. The gap raised an obvious question among regulators and observers: were more than forty licence holders sitting on unused permits speculatively, treating them as an asset to trade or wait out, rather than as a cultivation plan they intended to execute?
The ownership pattern tells its own story. Most of the licensees active on the ground were joint ventures involving partners from Germany, Switzerland and Canada -- established pharmaceutical and cannabis-industry players with the capital and compliance experience the regulations effectively demanded. Local Zimbabwean operators made up a distinctly small share of the list. Two state bodies jointly administer the system: the Medicines Control Authority of Zimbabwe (MCAZ) handles the pharmaceutical and regulatory vetting, while the Zimbabwe Investment and Development Agency (ZIDA) manages the investment side, a pairing that itself signals the scheme was built around attracting foreign capital rather than formalizing existing domestic growers.
The roster of names also shows real churn. Du Sud Cannabis, Swiss Bioceutical and Green Leaf Therapeutics all held licences that had expired by 2024, suggesting some early entrants didn't stay the course. Meanwhile newer operations have taken their place: Phamcan, Soul Leaf's site in Chegutu, Ndaka Holdings, THC Biomed's Victoria Falls Special site, Medicinal Cannabis Biotech's operation in Mazowe, and even a licensed site at Harare Airport, presumably chosen for logistics given the export-only nature of the crop. None of these are the kind of names you'd associate with a Binga smallholder cooperative.
2026: Zimbabwe Finally Cuts the Fees MPs Complained About
Photo via Unsplash.
On 4 and 5 August 2026, Finance Minister Mthuli Ncube announced a Cabinet-approved package of fee reductions -- cuts of up to 90% -- spanning more than thirteen sectors of the economy, with cannabis and hemp licensing singled out as one of the headline beneficiaries. For anyone who'd followed the SI 62 saga since 2018, the timing read like a direct, if very delayed, answer to the complaints MPs had raised at the scheme's launch.
The numbers were substantial. The MCAZ application processing fee dropped from US$10,000 to US$1,000. The five-year medicinal cannabis cultivation licence itself -- the fee that had locked out Binga farmers from day one -- fell from US$50,000 to US$15,000. Licence renewal costs dropped from US$50,000 to US$7,500, and the separate research fee fell from US$5,000 to US$1,000. Taken together, it's the most significant structural change to the cannabis licensing regime since the regulations were first gazetted eight years earlier.
Ncube didn't present this purely as a cannabis-equity fix, though. He tied the reform explicitly to a broader push to move tobacco farmers into industrial hemp cultivation, framing it as a hedge against the international anti-tobacco lobby that has steadily squeezed Zimbabwe's flue-cured tobacco export markets through health-driven trade pressure and shrinking demand in traditional buyer countries. That framing matters, because it tells you who Treasury actually had in mind when it cut these fees -- and it may not be the population parliament was worried about back in 2018.
Does Cheaper Mean Fairer This Time?
Photo by CRYSTALWEED cannabis via Unsplash.
Fifteen thousand dollars is a real improvement over fifty thousand, and nobody should pretend otherwise. But it's worth sitting with what fifteen thousand dollars still represents for a household in Binga District that has grown marijuana without any legal infrastructure, bank credit history or export contacts for generations. Even the lower figure is almost certainly out of reach without an outside investor fronting the capital -- which just reconstitutes the joint-venture pattern that defined the first eight years of the scheme, only with a smaller foreign equity stake required to get in the door.
And the fee cuts didn't touch the physical compliance requirements at all. Odour and pollen filtration systems, perimeter security fencing, surveillance equipment -- all of that remains exactly as costly as it was in 2018, because none of it was part of what Ncube's package addressed. Single-site licensing also survives untouched, meaning a smallholder with several scattered family plots still has to multiply fees and infrastructure costs across each one rather than operating under a single consolidated permit.
There's also a timing asymmetry worth naming plainly: the companies that have spent years building MCAZ and ZIDA relationships, navigating renewal paperwork and understanding the vetting process are far better positioned to exploit the new, cheaper fee structure immediately than any first-time Binga applicant trying to figure out the system from scratch. Established foreign joint ventures get a head start on expansion under lower costs before a genuinely new class of local applicants can even organize itself to apply.
Finally, it's worth separating two populations that keep getting conflated in coverage of this reform. Hemp diversification for tobacco growers -- mostly commercial farmers already embedded in export agriculture -- is a fundamentally different track from the informal marijuana growers in Binga that MPs were defending back in 2018. Ncube's announcement serves the first group far more directly than the second.
Give credit where it's due: the 2026 fee cuts fix the specific number MPs complained about in 2018. Fifty thousand dollars down to fifteen thousand for a licence, down to $7,500 for renewal -- that's a real concession to an eight-year-old argument, and Treasury deserves some acknowledgment for finally acting on it. But the number was never the whole problem, and the surrounding compliance architecture -- the fencing, the odour filtration, the single-site rule that multiplies costs for anyone with more than one plot -- was built for investors with capital and legal teams, not for a Binga household that's been quietly growing mbanje on family land since before independence.
The figure worth watching isn't the fee schedule. It's the activation rate. Fifteen of 57 licences actually under cultivation as of 2022 is not a healthy ratio for an industry eight years in, and the real test of this reform is whether that number climbs meaningfully once the lower fees take effect -- and, more specifically, whether any of the new entrants are Zimbabwean smallholders rather than another round of German, Swiss or Canadian joint ventures taking advantage of cheaper entry.
Ncube's own framing gives away where this is probably headed. He tied the reform to tobacco-to-hemp diversification, not to bringing Binga's existing marijuana growers into the legal economy. Those are genuinely different policy problems with different target populations, and Zimbabwe may be in the process of solving the one its Finance Ministry finds more strategically urgent -- tobacco export resilience -- while the one its own parliament flagged back in 2018 goes quietly unaddressed for another five years.
Sources
